Albert Einstein College of Medicine

Margaret Kielian

Jonathan R Lai

Julia Frei

Jose Quiroz

Ryan Malonis

Maofu Liao

Provided are high affinity anti-alphavirus antibodies or alphavirus-binding fragments thereof, as well as methods of use and devices employing such antibodies and/or fragments. Further provided are complementarity determining region (CDR) sequences of variable domain light chain (VL) and variable domain heavy chain (VH) sequences, and the methods of using the high affinity anti-alphavirus antibodies for treating different types of alphavirus infections.

Antibodies or antibody-fragments thereof targeting alphaviruses, and compositions and methods comprising same

Specific Dengue virus glycoprotein subunit E DIII variants and their uses in preventing and treating Dengue virus infection are disclosed.

Dengue virus glycoprotein E DIII variants and uses thereof

Methods of inhibiting viral infection of a eukaryotic cell by a target virus having a class II virus fusion protein are provided. Also provided are methods of screening a test compound for the ability to inhibit infection by a virus having a class II viral fusion protein. Additionally provided herewith are aqueous-soluble proteins comprising a portion of a class II viral fusion protein comprising a Domain III of the viral fusion protein.

Growing community of inventors

Pelham, NY, United States of America

Margaret Kielian